A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid leukemia patients after a higher rate of deaths was seen.